Neurocrine Biosciences (NBIX) Cash from Financing Activities (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Cash from Financing Activities for 17 consecutive years, with $63.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities rose 2021.21% year-over-year to $63.4 million; the trailing twelve-month figure through Jun 2026 stood at $60.2 million (up 115.64% YoY), and the FY2025 full-year result was -$38.3 million, up 92.13% from the prior year.
• Cash from Financing Activities climbed to $63.4 million in Q2 2026 per NBIX's latest filing, from -$86.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $69.9 million in Q1 2024 and bottomed at -$293.0 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged -$39.8 million across 5 years, with a median of $9.8 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities slumped 10203.45% in 2024, then soared 2021.21% in 2026.
• Over 5 years, Cash from Financing Activities stood at $24.6 million in 2022, then surged by 43.9% to $35.4 million in 2023, then slumped by 919.21% to -$290.0 million in 2024, then jumped by 112.86% to $37.3 million in 2025, then jumped by 69.97% to $63.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $63.4 million, -$86.1 million, and $37.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.